

Inpatient Antibiogram 2021- Urine Source only

Gram Negative-Urine Only	Aminoglycosides			Beta lactam/Beta lactam inhibitors			Carbapenems			Cephalosporin Class					Fluoroquinolones		Folate pathway inhibitor	Fosfomycin	Monobactams	Nitrofurans	
	Aminikacin	Gentamicin	Tobramycin	Amoxicillin/Clevulanate	Ampicillin	Ampicillin/Sulbactam	Piperacillin/Tazobactam	Ertapenem	Imipenem	Meropenem	Cefazolin	Cefazolin Urine	Cefepime	Ceftazidime	Ceftriaxone	Ciprofloxacin	Levofloxacin	Trimethoprim/Sulfamethoxazole	Fosfomycin	Aztreonam	Nitrofurantoin
Citrobacter freundii complex (22)		90	90	0	0	0	86	100	95	100	0		86	86	90	95	90				95
Enterobacter cloacae complex (52)		96	96	0	0	0	84	94		98	0		75	73	92	98	90				38
Escherichia coli (1127)		93	94	89	60	65	97	100	99	100		95	98	98	84	85	80		83		98
Escherichia coli , ESBL (80)		70	62	100			100	100	100	100			100	0	28	28	56	97			90
Klebsiella pneumoniae (165)		100	100	97	0	81	98	100	99	100		96	99	99	96	98	96			100	45
Proteus mirabilis (126)		94	92	92	79	90	100	100		100		85	96	95	71	74	80			100	0
Pseudomonas aeruginosa (73)	100	98	100		0		91		95	98		96	91		80	81				80	
Citrobacter koseri (29)		100	100	100	0	92	100	100	100	100	89		96	96	100	100	100				51
Klebsiella aerogenes (22)		100	100	0	0	0	86	100	100	100			86	85	100	100	100				40
Klebsiella oxytoca/Raoultella ornithinolytica (42)	100	92	92	85	0	40	85	100	100	100	34		97	92	90	100	85		100	90	
Klebsiella pneumoniae , ESBL (13)		61	46	0	0	0	100	100	100	100			0	0	46	76	30				30
Klebsiella varicola (27)		100	100	92	0	92	96	100	100	100	88		100	100	100	100	96				77
Morganella morganii (20)	100	75	85	0	0	10	95	100		100	0		80	80	55	60	55				0

Cefazolin predicts results for the oral agents-Cefaclor, cefdinir, cefpodoxime, cefprozil, cefuroxime axetil and loracarbef when used for therapy of uncomplicated UTI's due to E. coli, K. pneumoniae, and P. mirabilis. A valid statistical analysis should include 30 or more isolates, organisms with less than 30 isolates are listed for informational purpose only

COMMENTS:

1. Data are obtained from MIC and disk diffusion testing methods.
2. Isolate counts are in parenthesis to the right of the organism name.
3. Inpatient MRSA (methicillin resistant Staph aureus): In 2020, 127 of 423 (30.0%) inpatient Staph aureus isolates were MRSA. Prior years were as follows:2019-36.7%, 2018 - 39.4%, 2017 - 37.8%, 2016 - 41.3%, 2015 - 35.6%, 2014 - 52.5%.
4. ESBL (extended spectrum beta lactamases): In 2020, 188 of 2,573 (7.3%) E coli isolates (combined inpatient and outpatient) produced ESBL. Prior years as follows:2019-8.27%, 2018 - 8.3%, 2017 - 7.5%, 2016 - 8.1%, 2015 - 8.3%, 2014 - 6.8%, 2013 - 5%.
5. Penicillin Resistant Streptococcus pneumoniae: In 2020 no Penicillin Resistant Streptococcus pneumoniae. Prior year 2019, 1 of 34 (2.94%) Streptococcus pneumoniae isolates (combined inpatient and outpatient) were Penicillin resistant.

Inpatient Antibiogram 2021- Urine Source only

Gram positive-Urine only		Aminoglycosides	Ansamycin	Beta lactam/Beta lactam inhibitors	Cephalosprin Class	Fluoroquinolones	Folate pathway inhibitor	Glycopeptides	Lipopeptides	Nitrofurans	oxazolidinones	
	Organisms	Tetracycline	Gentamicin	Rifampin	Ampicillin	Oxacillin	Cefazolin	Levofloxacin	Trimethoprim/Sulfamethoxazole	Vancomycin	Daptomycin	Nitrofurantoin
Enterococcus faecalis (183)	23			98			85		99	100	100	98
Enterococcus faecium (16)	62			43			66		75	100		87
Staphylococcus epidermidis (26)	84	100	100		26	26	53		100	100	100	92
Staphylococcus aureus (28)	100	96	100		100	100	71	100	100	100	100	100
Methicillin Resistant Staphylococcus aureus (14)	92	92	100		0	0	14	78	100	100	100	100

Cefazolin predicts results for the oral agents-Cefaclor, cefdinir, cefpodoxime, cefprozil, cefuroxime axetil and loracarbef when used for therapy of uncomplicated UTI's due to E. coli, K. pneumoniae, and P. mirabilis.

A valid statistical analysis should include 30 or more isolates, organisms with less than 30 isolates are listed for informational purpose only

COMMENTS:

1. Data are obtained from MIC and disk diffusion testing methods.
2. Isolate counts are in parenthesis to the right of the organism name.
3. Inpatient MRSA (methicillin resistant Staph aureus): In 2020, 127 of 423 (30.0 %) inpatient Staph aureus isolates were MRSA. Prior years were as follows:2019-36.7%, 2018 - 39.4%, 2017 - 37.8%, 2016 - 41.3%, 2015 - 35.6%, 2014 -52.5%.
4. ESBL (extended spectrum beta lactamases): In 2020, 188 of 2,573 (7.3 %) E coli isolates (combined inpatient and outpatient) produced ESBL. Prior years as follows:2019-8.27%, 2018 - 8.3%, 2017 - 7.5%, 2016 - 8.1%, 2015 - 8.3%, 2014 - 6.8%, 2013 - 5%.
5. Penicillin Resistant Streptococcus pneumoniae: In 2020 no Penicillin Resistant Streptococcus pneumoniae. Prior year 2019, 1 of 34 (2.94%) Streptococcus pneumoniae isolates (combined inpatient and outpatient) were Penicillin resistant.

Inpatient Antibiogram 2021- Non Urine Source only

Gram Negative -Non-Urine Only

Organisms	Aminoglycosides			Beta lactam/Beta lactam inhibitors			Carbapenems			Cephalosporin Class			Fluoroquinolones		Folate pathway inhibitor	Monobactams		
	Amikacin	Gentamicin	Tobramycin	Amoxicillin/Clavulanate	Ampicillin	Ampicillin/Sulbactam	Piperacillin/Tazobactam	Ertapenem	Imipenem	Meropenem	Cefazolin	Cefepime	Ceftazidime	Ceftiozone	Ciprofloxacin	Levofloxacin	Trimethoprim/Sulfamethoxazole	Aztreonam
Citrobacter freundii complex (35)	94	91	0	0	0	88	100	97	100	0		88	88	91	97	88		
Enterobacter cloacae complex (89)	97	96	0	0	0	86	96		98	0	100	79	78	94	98	93	100	
Escherichia coli (1261)	100	93	94	88	60	65	97	100	99	100	84	100	98	98	84	86	80	87
Escherichia coli, ESBL (92)							98	98	100									
Klebsiella Pneumoniae (219)	100	99	95	0	80	95	100	99	100	85		98	98	97	99	97	100	
Proteus mirabilis (154)	100	95	93	93	83	91	100	100		2		96	96	75	78	83	100	
Pseudomonas aeruginosa (135)	100	97	98			92			95	98		96	91	84	85		82	
Citrobacter koseri (37)	100	100	100	0	94	100	100	100	100	83		97	97	100	100	100		
Klebsiella aerogenes (40)	100	100	0	0	75	100			100	0		75	76	100	100	100		
Klebsiella oxytoca/Raoultella ornithinolytica (72)	100	95	94	88	0	41	91	100	100	100	31	98	94	94	100	90	100	
Klebsiella Pneumoniae ESBL (16)							100	100	100									
Klebsiella varicola (29)		100	100	93	0	93	93	100	100	100	86	100	100	96	96	96		
Morganella morganii (35)	100	82	88	0	0	28	97	100		100	0	88	88	54	68	60		

Cefazolin predicts results for the oral agents-Cefaclor, cefdinir, cefpodoxime, cefprozil, cefuroxime axetil and loracarbef when used for therapy of uncomplicated UTI's due to E. coli, K. pneumoniae, and P. mirabilis. A valid statistical analysis should include 30 or more isolates, organisms with less than 30 isolates are listed for informational purpose only

COMMENTS:

1. Data are obtained from MIC and disk diffusion testing methods.
2. Isolate counts are in parenthesis to the right of the organism name.
3. Inpatient MRSA (methicillin resistant Staph aureus): In 2020, 127 of 423 (30.0 %) Inpatient Staph aureus isolates were MRSA. Prior years were as follows:2019-36.7%, 2018 - 39.4%, 2017 - 37.8%, 2016 - 41.3%, 2015 - 35.6%, 2014 - 52.5%.
4. ESBL (extended spectrum beta lactamases): In 2020, 188 of 2,573 (7.3 %) E coli isolates (combined inpatient and outpatient) produced ESBL. Prior years as follows:2019-8.27%, 2018 - 8.3%, 2017 - 7.5%, 2016 - 8.1%, 2015 - 8.3%, 2014 - 6.8%, 2013 - 5%.
5. Penicillin Resistant Streptococcus pneumoniae: In 2020 no Penicillin Resistant Streptococcus pneumoniae. Prior year 2019, 1 of 34 (2.94%) Streptococcus pneumoniae isolates (combined inpatient and outpatient) were Penicillin resistant.

Inpatient Antibiogram 2021-Non Urine Source only

Gram positive- Non Urine Only

Organisms	Penicillin		Tetracycline		Gentamicin		Aminoglycosides		Ansamycin		Beta lactam/Beta lactam inhibitors			Cephalosporin Class			Fluoroquinolones		Folate pathway inhibitor		Glycopeptides		Lincosamides		Lipopeptides		Macrolides		oxazolidinones	
	Penicillin	Tetracycline	Gentamicin	Gentamicin Synergy Screen	Rifampin	Ampicillin	Oxacillin	Penicillin (meningitis)	Penicillin (oral)	Cefazolin	Cefuroxime	Ceftriaxone	Ceftriaxone (meningitis)	Levofloxacin	Trimethoprim/Sulfamethoxazole	Vancomycin	Clindamycin	Daptomycin	Erythromycin	Linezolid										
Enterococcus faecalis (95)	100			76		97																								
Enterococcus faecium (17)				100		58																								
Staphylococcus epidermidis (58)		84	100		100	33			33					59	0	100	67	100	31	94										
Staphylococcus aureus (268)	0	95	98		99	99			99					84	97	100	85	100	69	100										
Methicillin Resistant Staphylococcus aureus (113)	0	87	93		99	0			0	100				26	86	100	72	100	20	100										
Streptococcus pneumoniae (16)	100						58	61				100	100	92		100	35		40											

Cefazolin predicts results for the oral agents-Cefaclor, cefdinir, cefpodoxime, cefprozil, cefuroxime axetil and loracarbef when used for therapy of uncomplicated UTI's due to E. coli, K. pneumoniae, and P. mirabilis. A valid statistical analysis should include 30 or more isolates, organisms with less than 30 isolates are listed for informational purpose only

COMMENTS:

1. Data are obtained from MIC and disk diffusion testing methods.
2. Isolate counts are in parenthesis to the right of the organism name.
3. Inpatient MRSA (methicillin resistant Staph aureus): In 2020, 127 of 423 (30.0 %) inpatient Staph aureus isolates were MRSA. Prior years were as follows:2019-36.7%, 2018 - 39.4%, 2017 - 37.8%, 2016 - 41.3%, 2015 - 35.6%, 2014-52.5%.
4. ESBL (extended spectrum beta lactamases): In 2020, 188 of 2,573 (7.3 %) E coli isolates (combined inpatient and outpatient) produced ESBL. Prior years as follows:2019-8.27%, 2018 - 8.3%, 2017 - 7.5%, 2016 - 8.1%, 2015 - 8.3%, 2014 - 6.8%, 2013 - 5%.
5. Penicillin Resistant Streptococcus pneumoniae: In 2020 no Penicillin Resistant Streptococcus pneumoniae. Prior year 2019, 1 of 34 (2.94%) Streptococcus pneumoniae isolates (combined inpatient and outpatient) were Penicillin resistant.